Semaglutide Side Effects: What Indian Patients Actually Experience

When semaglutide became affordable in India in March 2026, the questions that followed were predictable. Does it work? Am I eligible? How much does it cost? But the question that deserves more attention — and gets less — is a simpler one: what is it actually going to feel like?

Most side effect information available online is written for Western patients, drawn from trials that enrolled predominantly white populations. A real-world observational study conducted at a clinical centre in Andhra Pradesh — 100 Indian T2D patients on semaglutide over 12 weeks — gives a clearer picture of what Indian patients actually experience.^[1] That data, combined with the large STEP trial results, is what this article is built on.

The short version: most side effects are gastrointestinal, most are mild, and most improve significantly after the first 4–8 weeks. That is not a reassurance designed to get you to start the medication — it is what the evidence consistently shows. But knowing what to expect, and when to be concerned, makes a meaningful difference to whether treatment goes well.

The side effects most people experience

Gastrointestinal symptoms are the most common side effects of semaglutide. In the Indian clinical study, 43% of patients reported at least one GI symptom during the 12-week period.^[1] The STEP 1 trial, which enrolled over 1,900 participants globally, reported similar patterns — nausea in 44% of participants, diarrhoea in 30%, vomiting in 24%, and constipation in 24%.^[2]

What the numbers alone do not convey is the timing. These symptoms are most pronounced in the first 4–8 weeks of treatment, during the dose escalation phase when the body is adjusting to the medication. For most patients, they reduce significantly — and often resolve entirely — once the dose stabilises. This is not anecdotal; it is consistently documented across multiple trials and real-world studies.

Nausea — the most talked about symptom

Nausea is the side effect that gets the most attention, and for good reason — it is the most common. In the Indian study, 28% of patients experienced it.^[1] In global trials, the figure was higher, around 44%.^[2]

The nausea associated with semaglutide is typically described as mild to moderate. It tends to occur shortly after injection, particularly if a meal is eaten too quickly or in too large a quantity. Eating smaller portions, avoiding fatty or spicy food in the first weeks, and staying well hydrated all reduce it meaningfully. For most patients, nausea does not feel like being unwell — it feels more like a persistent fullness that makes overeating uncomfortable, which is, functionally, part of how the medication works.

An Indian dietary context worth noting

Traditional Indian thali meal with rice, dal, sabzi and roti — high-carbohydrate meals can intensify early semaglutide side effects

The Indian dietary pattern — often high in refined carbohydrates, rice, and fried foods — can intensify early GI side effects compared to the lower-carbohydrate diets typical of the Western trial populations. Endocrinologists across India have noted this in clinical practice. The combination of semaglutide's gastric-slowing effect and a heavy traditional meal is more likely to trigger nausea than a lighter meal.

This is not a reason to avoid the medication. It is a reason to approach the first few weeks with some dietary adjustment — smaller portions, slower eating, and spacing out meals. The medication does not require a radical change in diet, but it does reward a more mindful approach to eating.

What most patients do not need to worry about

The Indian clinical data offers a useful reality check on severity. Of the 43% of patients who experienced GI side effects, 58% had symptoms classified as mild.^[1] Only 14% of those who had side effects discontinued treatment entirely — meaning the overall discontinuation rate due to side effects was around 6% of all patients studied. The remaining patients either managed through the initial period or had their dose temporarily reduced, with 66.7% of those who had dose reductions successfully continuing therapy afterwards.^[1]

That is a different picture from the one patients often carry into treatment. The concern — understandable, given how side effects are discussed online — is often that the medication will make daily functioning difficult. For the large majority of patients, that is not what happens.

The side effects that require medical attention

Most side effects from semaglutide are manageable. A small number are serious and require prompt medical review. These are not reasons to avoid the medication, but they are reasons to start under physician supervision and to know the warning signs.

Pancreatitis

Acute pancreatitis has been reported as a rare adverse event in semaglutide trials.^[3] The incidence is low — under 1% in clinical populations — but the symptom to watch for is severe, persistent abdominal pain that radiates to the back. Anyone with a history of pancreatitis should not take semaglutide at all; for those without that history, the risk is low but real, and upper abdominal pain that does not resolve within a few hours should be assessed by a doctor promptly.

Gallbladder disease

The STEP 1 trial found a 2–3% rate of gallbladder events — primarily gallstones — in participants taking semaglutide.^[2] This is thought to be related to rapid weight loss rather than a direct drug effect. The practical implication: right upper abdominal pain, particularly after fatty meals, should be reported to a physician.

For patients with type 2 diabetes: diabetic retinopathy

In the SUSTAIN-6 trial, a small but statistically significant increase in diabetic retinopathy complications was observed in T2D patients who achieved rapid blood sugar improvement early in treatment.^[4] The mechanism is not fully understood, but the practical recommendation is clear: T2D patients with any pre-existing eye disease should have an ophthalmology review before starting semaglutide.

The one side effect specific to Indian patients: muscle loss

Indian man exercising outdoors — resistance exercise is recommended alongside semaglutide to protect muscle mass

This deserves its own section because it is underemphasised in most Western-oriented content — and disproportionately relevant to Indian patients.

The "thin-fat Indian phenotype" — documented extensively by the ICMR-INDIAB studies — describes how Indians carry a lower proportion of skeletal muscle relative to body fat compared to Western populations at equivalent BMI.^[5] When semaglutide produces rapid weight loss, a portion of that weight loss can include muscle mass, particularly in patients who do not maintain adequate protein intake and physical activity. In Indian patients, who already tend to start with lower muscle reserves, this risk is clinically meaningful.

The response to this is practical, not alarming. The clinical recommendation is:

Maintain protein intake of at least 1.2–1.5g per kg of body weight per day during treatment
Include resistance exercise (bodyweight, weights, or resistance bands) at least twice weekly
Do not skip meals in an attempt to accelerate weight loss — the medication already reduces appetite significantly

Indian protein sources that work well during treatment: eggs, paneer, dal, chicken, curd, and fish. The goal is not a dramatic dietary overhaul but a deliberate prioritisation of protein at each meal.

Practical guidance for managing side effects

Based on the clinical evidence and Indian-specific context, these are the most useful practical steps for patients starting semaglutide:

For nausea

Eat smaller meals — the medication slows gastric emptying, so large portions intensify the sensation of fullness
Avoid very oily, spicy, or fried foods in the first month
Inject in the evening if nausea peaks a few hours after dosing — most people sleep through the peak
Eat slowly and stop before feeling full

For diarrhoea and constipation

Stay well hydrated — 2–3 litres of water daily
Increase dietary fibre gradually for constipation
Avoid greasy food if diarrhoea is prominent
Both typically resolve within the first few weeks

For muscle preservation

Prioritise protein at every meal — aim for 25–30g per meal
Add resistance exercise twice weekly, even light bodyweight work
Do not skip meals

When to contact your doctor

Severe abdominal pain that does not resolve — potential pancreatitis
Right upper abdominal pain after eating — potential gallbladder event
Vision changes — requires prompt ophthalmology review for T2D patients
Persistent vomiting preventing food or fluid intake — risk of dehydration
Any side effect that significantly affects daily functioning beyond the first 4 weeks

The bigger picture

Indian woman in consultation with a doctor — an open conversation about what to expect from semaglutide makes a meaningful difference to outcomes

The clinical data on semaglutide tolerability is actually more reassuring than the conversation around it suggests. The discontinuation rate due to side effects in the Indian study was 6% — meaning 94% of patients continued treatment.^[1] Globally, the STEP trials showed 75–80% of patients who experienced early GI side effects saw significant improvement after the first 4–8 weeks.^[2]

The patients who do best tend to be those who start with realistic expectations, make modest dietary adjustments in the first month, maintain protein intake and some physical activity throughout, and have a physician they can contact if something feels wrong. None of those things are difficult — but they are all meaningful.

If you want to know whether semaglutide is appropriate for you before having that conversation with a doctor, GLP-1 Check's free 5-minute assessment uses Indian clinical thresholds — including screening for the contraindications that make side effects more likely — to give you a Green, Amber, or Red readiness score.

Key data points

43% of Indian T2D patients on semaglutide experienced GI side effects in a 12-week clinical study — 58% of those were mild^[1]
Overall discontinuation rate due to side effects: 6% in the Indian study^[1]
66.7% of patients who needed dose reduction successfully continued therapy after adjustment^[1]
Nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) — STEP 1 trial global data^[2]
75–80% of patients who experience early GI side effects see significant improvement by weeks 4–8^[2]
Indians carry lower skeletal muscle mass per kg body weight — muscle preservation requires deliberate attention during treatment^[5]

References

Kodela MP, Sasi NOA, Pamarthy PPR. Evaluating gastrointestinal side effects and discontinuation rates of semaglutide in routine clinical practice: A prospective observational study conducted at Konaseema Institute of Medical Sciences and Research Foundation, Amalapuram, Andhra Pradesh, India.. Student's Journal of Health Research Africa. 2025;6(9). DOI
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine. 2021;384:989–1002. PubMed
Endocrine Society of India (ESI). Clinical Practice Guidelines for the Evaluation and Management of Obesity in India. PMC
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6 Trial). New England Journal of Medicine. 2016;375:1834–1844. PubMed
ICMR-INDIAB-23: High Prevalence of Metabolic Obesity in India. Indian Journal of Medical Research. 2025. PMC

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified physician before starting any treatment. Semaglutide is a prescription drug in India and must only be taken under medical supervision.